Lataa...
Two RSV Platforms for G, F, or G+F Proteins VLPs
Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available for some high risk infants. To support anti-viral a...
Tallennettuna:
| Julkaisussa: | Viruses |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7551478/ https://ncbi.nlm.nih.gov/pubmed/32824936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/v12090906 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|